Literature DB >> 2188483

Mortality and causes of death in schizophrenic patients in Denmark.

P B Mortensen1, K Juel.   

Abstract

A cohort consisting of 6178 people that were psychiatric inpatients with a clinical schizophrenia diagnosis in 1957 were followed up from 1957 through 1986, and their cause-specific mortality was determined. Mortality from cardiovascular diseases, lung diseases, gastrointestinal and urogenital disorders, accidents and suicide was increased, whereas mortality from cerebrovascular disorders was reduced. In the male patients cancer mortality was reduced whereas cancer mortality in the female patients was increased. Mortality from a number of causes that theoretically could be associated with side effects from neuroleptics was increased. Mortality from some causes of death used as a measurement of the quality of medical care was found to be slightly increased. Further studies of the quality of the medical care provided to schizophrenic patients and of the association between neuroleptic medication and mortality are needed.

Entities:  

Mesh:

Year:  1990        PMID: 2188483     DOI: 10.1111/j.1600-0447.1990.tb05466.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  20 in total

1.  Twenty-five year mortality of a community cohort with schizophrenia.

Authors:  Steve Brown; Miranda Kim; Clemence Mitchell; Hazel Inskip
Journal:  Br J Psychiatry       Date:  2010-02       Impact factor: 9.319

2.  Schizophrenia--a predictor of suicide during the second half of life?

Authors:  Annette Erlangsen; William W Eaton; Preben Bo Mortensen; Yeates Conwell
Journal:  Schizophr Res       Date:  2011-10-22       Impact factor: 4.939

3.  Mortality of people suffering from mental illness: a study of a cohort of patients hospitalised in psychiatry in the north of France.

Authors:  Claire-Lise Charrel; Laurent Plancke; Michaël Genin; Laurent Defromont; François Ducrocq; Guillaume Vaiva; Thierry Danel
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-06-11       Impact factor: 4.328

4.  Behavioral effects of phencyclidine on nicotine self-administration and reinstatement in the presence or absence of a visual stimulus in rats.

Authors:  Natashia Swalve; Steven T Pittenger; Rick A Bevins; Ming Li
Journal:  Psychopharmacology (Berl)       Date:  2015-04-07       Impact factor: 4.530

5.  Effects of the phencyclidine model of schizophrenia and nicotine on total and categorized ultrasonic vocalizations in rats.

Authors:  Natashia Swalve; Michele M Mulholland; Tiffany D Schulz; Ming Li
Journal:  Behav Pharmacol       Date:  2016-06       Impact factor: 2.293

Review 6.  Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

Authors:  K G Terkelsen; A Menikoff
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

7.  A widening longevity gap between people with schizophrenia and general population: A literature review and call for action.

Authors:  Ellen E Lee; Jinyuan Liu; Xin Tu; Barton W Palmer; Lisa T Eyler; Dilip V Jeste
Journal:  Schizophr Res       Date:  2017-09-28       Impact factor: 4.939

8.  Prospective trial of customized adherence enhancement plus long-acting injectable antipsychotic medication in homeless or recently homeless individuals with schizophrenia or schizoaffective disorder.

Authors:  Martha Sajatovic; Jennifer Levin; Luis F Ramirez; David Y Hahn; Curtis Tatsuoka; Christopher S Bialko; Kristin A Cassidy; Edna Fuentes-Casiano; Tiffany D Williams
Journal:  J Clin Psychiatry       Date:  2013-12       Impact factor: 4.384

9.  Beat-to-beat heart rate and QT interval variability in first episode neuroleptic-naive psychosis.

Authors:  Ripu D Jindal; Matcheri S Keshavan; Kevin Eklund; Angela Stevens; Debra M Montrose; Vikram K Yeragani
Journal:  Schizophr Res       Date:  2009-07-01       Impact factor: 4.939

10.  Mortality of Finnish acute psychiatric hospital patients.

Authors:  Heidi Honkonen; Aino K Mattila; Klaus Lehtinen; Teemu Elo; Riina Haataja; Matti Joukamaa
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05-13       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.